Joshua Reuss, MD, FASCO (@Joshua_Reuss) ranks #20 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6, OptiTROP-Lung05, DESTINY-Lung04. CMS Open Payments lists $37,992 in 2025 general payments.
At a Glance
- 8 posts naming a trial in 2026
- 9 trials discussed by name
- Lung Cancer: US #20, Global #45 · 14 physicians engaged
- CMS Open Payments lists $37,992 in 2025 general payments.
This Month
What Joshua Reuss, MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Joshua Reuss, MD, FASCO
Physicians who reposted Joshua Reuss, MD, FASCO’s trial posts most often in 2026.
- GL
gilberto lopes4 reposts - SV
Stephen V Liu, MD3 reposts - EK
Eric K. Singhi, MD2 reposts - VA
Vanya Aggarwal1 repost - CK
Chul Kim1 repost - HS
Hawaii Specialist1 repost - ES
Edgardo S. Santos, M.D., FACP, FASCO1 repost - DN
Dr NAVDEEP SINGH DM ( AIIMS ) New Delhi1 repost - CO
Coral Olazagasti, MD1 repost - DL
Dr. Luis E. Raez1 repost
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #20 | #45 | 14 | 24 | Full ranking |
What Colleagues Are Saying About Joshua Reuss, MD, FASCO
2026 posts by fellow physicians that mention @Joshua_Reuss, quoted word for word.
Our own @Joshua_Reuss walking us through periop chemoIO in resectable NSCLC. Clear benefits demonstrated across multiple phase III trials. Remaining Qs include neoadj vs perioperative approach, potential role in borderline resectable NSCLC. @TLCconference #TexasLung2026 https://t.co/xs34kdEBo2
Honored to serve on the @ASCO Lung Cancer Guidelines Panel under the leadership of our co-chairs @Joshua_Reuss @Sonampuri @LudaBazhenovaMD #NatashaLeighl Our latest publication here: https://t.co/afTiTU6Lt7 #ASCO26 https://t.co/LsUcVV9lBH
Grateful for the opportunity to present HARMONi-6, WU-KONG28, and OptiTROP-Lung05 at #Yellowstone2026 Best of @ASCO. Beautiful views and #mini @LombardiCancer reunion with @Joshua_Reuss. #lcsm #nsclc #jacksonhole Thanks again #MSOS #ISCO #WSOS ❤️ https://t.co/8Y3k7YcSNv
Trials Joshua Reuss, MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 1 | #63 of 74 | Oct 3, 2026 |
| OptiTROP-Lung05 | 1 | #19 of 19 | Oct 3, 2026 |
| DESTINY-Lung04 | 1 | #15 of 37 | Sep 14, 2026 |
| REZILIENT3 | 1 | #20 of 27 | Sep 14, 2026 |
| ARROS-1 | 1 | #19 of 26 | Sep 14, 2026 |
| ADAURA | 1 | #19 of 41 | Sep 13, 2026 |
| PAPILLON | 1 | #11 of 26 | Sep 13, 2026 |
| FLAURA2 | 1 | #4 of 25 | Jan 24, 2026 |
| MARIPOSA | 1 | #5 of 14 | Jan 24, 2026 |
Joshua Reuss, MD, FASCO on HARMONi-6
Dr. @jennifermarksmd presents updates in adv NSCLC at Yellowstone 2026 Best of @ASCO including HARMONi-6, WU-KONG28 and OptiTROP-Lung05. Will be impt to see how these agents perform in global studies and in case of sunvo, would just like ACCESS to drug! Hopefully coming soon!! https://t.co/BtDvg1flYb
Joshua Reuss, MD, FASCO on OptiTROP-Lung05
Dr. @jennifermarksmd presents updates in adv NSCLC at Yellowstone 2026 Best of @ASCO including HARMONi-6, WU-KONG28 and OptiTROP-Lung05. Will be impt to see how these agents perform in global studies and in case of sunvo, would just like ACCESS to drug! Hopefully coming soon!! https://t.co/BtDvg1flYb
Joshua Reuss, MD, FASCO on DESTINY-Lung04
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs 8.3mo (HR 0.63) ✅️ ORR 7O vs 45% ☑️ No OS diff observed 1st ph3 study for HER2-targeted Rx in adv HER2m NSCLC. Efficacy by mutation type & CNS efficacy will help in agent selection. https://t.co/wRbyeY4eZd
Joshua Reuss, MD, FASCO on REZILIENT3
Dr. @danieltanmd presents ph3 REZILIENT3 zipalertinib+chemo vs chemo #WCLC26. ✅️ PFS 14.5mo vs 8.5mo (HR 0.50) ❔️ OS data remains immature ☢️ 9.3% deaths in combo arm CANNOT be overlooked An emerging frontline Rx for EGFR exon20 but aggressive toxicity mgmt will be critical https://t.co/2MHVcQyzMA
Joshua Reuss, MD, FASCO on ARROS-1
Dr. @alexdrilon presents TKI-naive cohort from ph 1/2 ARROS-1 Trial. #WCLC26 ✅️ impressive ORR 94% ✅️ mPFS NR (early cutpoint) ☢️ dose reduction d/t AEs 23% (12% emergent, 11% related). 5% dc'd. Durability of systemic/intracranial efficacy will be 🔑 for 1st line choice https://t.co/BoF6ipBCLf
Joshua Reuss, MD, FASCO on ADAURA
Dr. @DrRoyHerbst presents exploratory 8-year analysis of ADAURA Trial at #WCLC26. At 8 years: ✅️ durable OS benefit across populations (OS HR 0.53 in stage II/III pop) ✅️ 8yr landmark 74% vs 58% While exploratory, reinforces durable efficacy of this now SOC approach. https://t.co/z7ADbenyy8
Joshua Reuss, MD, FASCO on PAPILLON
Thrilled to see my 🌟 @LombardiCancer colleague Dr @chulkimMD present final OS data for phase 3 PAPILLON Study #WCLC26 . mOS 34.3mo w/ ami-chemo vs 27.9mo chemo (HR 0.87, 95% CI 0.66-1.14). 76% x-over in chemo arm to ami. Durable efficacy apparent when adjusting for x-over. https://t.co/GQ8oROq33z
Joshua Reuss, MD, FASCO on FLAURA2
Dr. @JuliaRotow makes her case for FLAURA2 osimertinib+chemotherapy in EGFRm NSCLC at #WinterLung26. Benefit extends beyond classical "high risk" subgroups. https://t.co/meVl7Flh3y
Joshua Reuss, MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Published today on @myESMO concurrent with #ELCC26 the 3rd edition of 'Thoracic Tumors: Essentials for Clinicians'. A must-have resource for trainees & practicing clinicians alike. Had fun penning the early-stage NSCLC section with Dr. Tina Cascone! https://t.co/Hk3i3abwq4
Dr. @SusanScottMD makes a strong argument to make osimertinib great again at #WinterLung26. https://t.co/ZIVv7bCrWq
Dr. @lungoncdoc takes us through the rapidly evolving space of HER2-mutated NSCLC. Great to have multiple innovations in the subsequent line space. Looking forward to moving these forward to the frontline together with innovative combination strategies. ##WinterLung26 @gotoPER https://t.co/nmFUehoyYP
FDA approves zidesamtinib for advanced ROS1+ NSCLC treated with prior ROS1-TKI. Excellent news for our patients adding this next-generation CNS-penetrant TKI to our armamentarium! @ros1cancer https://t.co/kP437RrQyb
Dr. @LudaBazhenovaMD with an excellent breakdown of emerging/approved frontline treatment strategies in EGFR exon20ins+ adv NSCLC. Grateful to have multiple options, but many factors to consider before deploying a particular treatment. #WCLC26 https://t.co/8kjqi3c0QK
Industry Payments
CMS Open Payments · 2025 general payments
$37,992 across 32 payments